SCHEMBL3021138

SCHEMBL3021138

Cc1ccccc1Cc1csc(N2CCC(S(=O)(=O)c3ccc(Br)cc3)CC2)n1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.39
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
NPC1 O15118 2/20 0.37
MAPT P10636 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
LMNA P02545 2/20 0.35
MAPK1 P28482 1/20 0.35
PIK3CA P42336 1/20 0.34
HTR2A P28223 2/20 0.34
DNM1L O00429 4/20 0.34
HTR2C P28335 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015608 0.93 SMN1; SMN2 (0.38) GBA1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL3002378 0.92 GBA1 (0.46) GBA1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL3017650 0.91 GBA1 (0.39) GBA1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL3017247 0.91 GBA1 (0.38) GBA1MEN1KMT2AMAPTLMNA
SCHEMBL3012981 0.90 KDM4E (0.41) GBA1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL3017287 0.90 DNM1L (0.34) GBA1MEN1KMT2ARAB9ANPC1
SCHEMBL3000622 0.89 RAB9A (0.37) GBA1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL3024075 0.89 HSD11B1 (0.38) GBA1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL3013639 0.89 GBA1 (0.38) GBA1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL3008969 0.88 MEN1 (0.39) GBA1MEN1KMT2ARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GBA1 4/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.